172 related articles for article (PubMed ID: 37175658)
21. Synthesis and biological evaluation of 1-phenyl-4,6-dihydrobenzo[b]pyrazolo[3,4-d]azepin-5(1H)-one/thiones as anticancer agents.
Parupalli R; Akunuri R; Spandana A; Phanindranath R; Pyreddy S; Bazaz MR; Vadakattu M; Joshi SV; Bujji S; Gorre B; Yaddanapudi VM; Dandekar MP; Reddy VG; Nagesh N; Nanduri S
Bioorg Chem; 2023 Jun; 135():106478. PubMed ID: 36958121
[TBL] [Abstract][Full Text] [Related]
22. Molecular Spectroscopy Evidence of 1,3,5-Tris(4-carboxyphenyl)benzene Binding to DNA: Anticancer Potential along with the Comparative Binding Profile of Intercalation via Modeling Studies.
Wani TA; Zargar S
Cells; 2023 Apr; 12(8):. PubMed ID: 37190029
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
24. Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2.
Shaker AMM; Shahin MI; AboulMagd AM; Abdel Aleem SA; Abdel-Rahman HM; Abou El Ella DA
Bioorg Chem; 2022 Dec; 129():106143. PubMed ID: 36191430
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
26. Discovery of 1-(5-bromopyrazin-2-yl)-1-[3-(trifluoromethyl)benzyl]urea as a promising anticancer drug via synthesis, characterization, biological screening, and computational studies.
Mohammed YHI; Shamkh IM; Alharthi NS; Shanawaz MA; Alzahrani HA; Jabbar B; Beigh S; Alghamdi S; Alsakhen N; Khidir EB; Alhuthali HM; Karamalla THE; Rabie AM
Sci Rep; 2023 Dec; 13(1):22824. PubMed ID: 38129413
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
[TBL] [Abstract][Full Text] [Related]
28. Hydrazide-hydrazones as Small Molecule Tropomyosin Receptor Kina se A (TRKA) Inhibitors: Synthesis, Anticancer Activities,
Alam MS; Lee DU
Med Chem; 2022; 19(1):47-63. PubMed ID: 35490310
[TBL] [Abstract][Full Text] [Related]
29. Design, Synthesis, Anticancer Evaluation and Docking Studies of Novel Heterocyclic Derivatives Obtained via Reactions Involving Curcumin.
Borik RM; Fawzy NM; Abu-Bakr SM; Aly MS
Molecules; 2018 Jun; 23(6):. PubMed ID: 29890691
[TBL] [Abstract][Full Text] [Related]
30. Half-Lantern Cyclometalated Platinum(II) Complexes as Anticancer Agents: Molecular Docking, Apoptosis, Cell Cycle Analysis, and Cytotoxic Activity Evaluations.
Hajipour F; Mahdavinia M; Fereidoonnezhad M
Anticancer Agents Med Chem; 2022; 22(6):1149-1158. PubMed ID: 34259151
[TBL] [Abstract][Full Text] [Related]
31. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
El-Adl K; Ibrahim MK; Alesawy MSI; Eissa IH
Bioorg Med Chem; 2021 Jan; 30():115958. PubMed ID: 33360576
[TBL] [Abstract][Full Text] [Related]
32. Targeting the interplay between MMP-2, CA II and VEGFR-2 via new sulfonamide-tethered isomeric triazole hybrids; Microwave-assisted synthesis, computational studies and evaluation.
Reda Aouad M; Almehmadi MA; Faleh Albelwi F; Teleb M; Tageldin GN; Abu-Serie MM; Hagar M; Rezki N
Bioorg Chem; 2022 Jul; 124():105816. PubMed ID: 35489270
[TBL] [Abstract][Full Text] [Related]
33. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
34. New Indazol-Pyrimidine-Based Derivatives as Selective Anticancer Agents: Design, Synthesis, and In Silico Studies.
Al-Tuwaijri HM; Al-Abdullah ES; El-Rashedy AA; Ansari SA; Almomen A; Alshibl HM; Haiba ME; Alkahtani HM
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175074
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, Molecular Docking and Biological Evaluation of Quinolone Derivatives as Novel Anticancer Agents.
Li J; Zheng TC; Jin Y; Xu JG; Yu JG; Lv YW
Chem Pharm Bull (Tokyo); 2018 Jan; 66(1):55-60. PubMed ID: 29118308
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, molecular modeling and biological evaluation of new pyrazolo[3,4-b]pyridine analogs as potential antimicrobial, antiquorum-sensing and anticancer agents.
El-Gohary NS; Gabr MT; Shaaban MI
Bioorg Chem; 2019 Aug; 89():102976. PubMed ID: 31103494
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and mechanistic studies of novel imidazo[1,2-a]pyridines as anticancer agents.
Ismael AS; Amin NH; Elsaadi MT; Abdel-Rahman HM
Bioorg Chem; 2022 Nov; 128():106042. PubMed ID: 35878430
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, anticancer evaluation and molecular docking studies of new heterocycles linked to sulfonamide moiety as novel human topoisomerase types I and II poisons.
Halawa AH; Elgammal WE; Hassan SM; Hassan AH; Nassar HS; Ebrahim HY; Mehany ABM; El-Agrody AM
Bioorg Chem; 2020 May; 98():103725. PubMed ID: 32199303
[TBL] [Abstract][Full Text] [Related]
39. Revisiting ageless antiques; synthesis, biological evaluation, docking simulation and mechanistic insights of 1,4-Dihydropyridines as anticancer agents.
Sidhom PA; El-Bastawissy E; Salama AA; El-Moselhy TF
Bioorg Chem; 2021 Sep; 114():105054. PubMed ID: 34146919
[TBL] [Abstract][Full Text] [Related]
40. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
